Bifidobacterium longum – 04 (DSM 23233)

Tabella dei contenuti

Clinical indications

antipathogenic activity, cholesterol management, mood and sleep quality, weight management, Cardiovascular health

Area of use

Cardiology blend | Cholesterol management

  • Bifidobacterium lactis – MB2409 (DSM 23733)
  • Bifidobacterium bifidum – MB109 (DSM 23731)
  • Bifidobacterium longum – 04 (DSM 23233)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1 billion CFU/strain


FUNCTIONALITY
Cardiovascular health • Cholesterol lowering

Scientific support

Human clinical trial
Guardamagna O. et al. Bifidobacteria supplementation: effects on plasma lipid profile in dyslipidemic children. Nutrition (2014), doi: 10.1016/ j.nut. 2014.01.014.

In vitro and in vivo testing
Bordoni et al. Cholesterol-lowering probiotics: in vitro selection and in vivo testing of Bifidobacteria. Appl. Microbiol. Biotechnol. 2013. 97:8273-8281.


Dietetics strain | Weight management

Characteristics

DAILY DOSAGE
1 billion CFU


FUNCTIONALITY
Restoration of a better dietary ω-6/ω-3 balance • Conjugated linoleic acids (CLA) production • Prospective use in the treatment of obesity • Cholesterol management

Scientific support

Internal data available upon request


Gut-brain blend | Mood and sleep quality

  • Bifidobacterium longum – 04 (DSM 23233)
  • Lactobacillus fermentum – LF16 (DSM 26856)
  • Lactobacillus plantarum – LP01 (LMG P-21021)
  • Lactobacillus rhamnosus – LR06 (DSM 21981)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1 billion cfu/afu per strain


FUNCTIONALITY
Improvement of the quality of sleep • Reduction of fatigue and anger • Improvement of mood • Inhibition of E. coli and Candida

Scientific support

Human clinical trial
Marotta A. et al., Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality, 2019 Frontiers in Psychiatry.